Abstract: A system includes a hard network-on-chip (NOC) and lookup table random access memory (LUTRAM) circuits usable as logic gates in a user design for an integrated circuit and reprogrammable in a user mode of the integrated circuit through the hard NOC. The LUTRAM circuits are reconfigurable during the user mode of the integrated circuit by providing a bit through the hard NOC for storage in the one of the LUTRAM circuits.

Abstract: Systems and methods for customizing medical tapes from a roll stock at customer use sites are provided. The system includes a tape converting machine where an adhesion modification mechanism is configured to modify adhesion properties of the tape from the roll stock, automatically or based on received customization instructions.

Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.

Abstract: Systems and methods described herein may relate to burst sampling of an integrated circuit device. Such a system may include a first logic access block including a data register and a second logic access block including a memory column. The memory column may be configurable to operate as a First In, First Out (FIFO), user lookup table (LUT) mode, or as user random access memory (RAM). The memory column may store data sampled from the data register for any number of clock cycles and the data may be sampled at the speed of a clock of a device under test (DUT).

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: To increase logic density at relatively low silicon area and power cost and limiting the adverse impacts on routability and placement flexibility, an enhanced programmable logic architecture may be implemented with a hybrid architecture including a combination of the configurable gate-based logic and lookup tables (LUTs) (and/or other heterogeneous logic resources). The hybrid combination of heterogeneous logic resources may share one or more interconnects and inputs, such that the various logic resources may be cascaded rather than mutually exclusive. Sharing of the interconnect may be beneficial as the interconnect may use the majority of the area, power, and delay on the FPGA, more than the logic itself. Accordingly, the shared interconnects may reduce die area, power consumption, and delay on the FPGA. The configurable gate-based logic may include Configurable NOR-Inverts (CNIs). The CNIs may share inputs with existing LUTs or may use LUTs outputs as OR-Invert inputs.

Abstract: To utilize unused or underused input and output pins without a large and undesirable impact on power and die area consumption, an adaptive logic module (ALM) of a programmable logic device may be implemented with an additional 2LUT to improve small function packing density and wide function mapping coverage. The 2LUT may also serve as a route-through to provide direct access to ALM registers with or without input inversion. The enhanced ALM may also use route-through configurations of the additional 2LUT to improve the connectivity of the ALM inputs and outputs.

Abstract: The present disclosure relates compounds of Formula (I?): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.

Abstract: Systems and methods for non-destructive readback and writeback of an integrated circuit system are provided. Such a system may include an adaptive logic element including a first register pair. The first register pair may include a first register operating at a first frequency and a second register operating at a second frequency. The second frequency may be equal to or lower than the first frequency. The second register may store data from the first register. The adaptive logic element may also include a first clock providing a first clock signal to the first register and a second clock providing a second clock signal. The adaptive logic element may also include a multiplexer that may select the first clock signal or the second clock signal as a clock source for the second register.

Abstract: A system includes a computing device a personal protective equipment (PPE) device. The PPE device is configured to be worn by a worker and includes and at least one physiological sensor configured to generate physiological data indicative of one or more physiological characteristics of a worker. The computing device is configured to determine a safety risk score for the worker based at least in part on the physiological data and a risk profile associated with the worker.

Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: An integrated circuit includes a logic circuit block that includes a first adaptive logic module configurable to store a first state of a first signal received from a device-under-test in a first register, a second adaptive logic module configurable to store a second state of a second signal in a second register during a user mode of the integrated circuit simultaneously with the first state of the first signal being stored in the first register, and a third adaptive logic module configurable to store a third state of the first signal in a third register. The first and the third states of the first signal are stored for consecutive clock cycles in the first register and the third register. The logic circuit block is configurable to scan out the second state in the second register and the third state in the third register.

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.